BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/17/2021 6:19:34 AM | Browse: 913 | Download: 2237
 |
Received |
|
2021-01-11 18:32 |
 |
Peer-Review Started |
|
2021-01-11 18:33 |
 |
First Decision by Editorial Office Director |
|
2021-01-23 03:21 |
 |
Return for Revision |
|
2021-01-23 03:21 |
 |
Revised |
|
2021-01-24 20:40 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2021-02-23 01:22 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2021-03-01 04:24 |
 |
Articles in Press |
|
2021-03-01 04:24 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2021-03-08 04:38 |
 |
Publish the Manuscript Online |
|
2021-03-17 06:19 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Review |
| Article Title |
Genotype 3-hepatitis C virus’ last line of defense
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Dorota Zarębska-Michaluk |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Dorota Zarębska-Michaluk, N/A, Professor, Department of Infectious Diseases, Jan Kochanowski University, Żeromskiego 5, Kielce 25-369, Świętokrzyskie, Poland. dorota1010@tlen.pl |
| Key Words |
Hepatitis C virus; Genotype 3; Antiviral treatment; Interferon; Direct-acting antivirals; Pangenotypic |
| Core Tip |
Genotype 3 which is second in frequency worldwide, is unique among genotypes of hepatitis C virus in its higher rate of steatosis, accelerated fibrosis progression, and lower cure rates. This paper describes the genotype-specific mechanisms of liver injury and provides an overview of therapeutic options. Currently, available highly potent pangenotypic regimens have revolutionized the treatment of genotype 3 infection, however, patients with liver cirrhosis and those who fail to response to direct-acting antiviral therapy still present a therapeutic challenge. |
| Publish Date |
2021-03-17 06:19 |
| Citation |
Zarębska-Michaluk D. Genotype 3-hepatitis C virus’ last line of defense. World J Gastroenterol 2021; 27(11): 1006-1021 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i11/1006.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i11.1006 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.